AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Dyno Nobel Ltd

3.330

+0.1404.39%

Volume:3.55M

Turnover:11.64M

Market Cap:5.95B

PE:-119.67

High:3.340

Open:3.240

Low:3.240

Close:3.190

52wk High:3.600

52wk Low:2.062

Shares:1.79B

Float Shares:1.65B

Volume Ratio:1.33

T/O Rate:0.22%

Dividend:0.12

Dividend Rate:3.57%

EPS(TTM):-0.028

EPS(LYR):-0.028

ROE:3.20%

ROA:4.16%

PB:1.34

PE(LYR):-119.67

Loading ...

Overview Company News Filings

Concept

no data

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

Dyno Nobel Ltd-Non-Executive Director Appointment

THOMSON REUTERS

Ascletis Announces Positive Topline Results from Its Phase III Open-Label Study of Denifanstat (ASC40), a First-in-Class, Once-Daily Oral FASN Inhibitor for Acne

With 52% ownership in Dyno Nobel Limited (ASX:DNL), institutional investors have a lot riding on the business

Simply Wall St.

Insufficient Growth At Dyno Nobel Limited (ASX:DNL) Hampers Share Price

Simply Wall St.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Trading app for stocks, options & ETFs","description":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","keywords":"tiger brokers,tiger brokers au,tiger brokers australia,tiger trade,tiger trading,australia stock platform,US option,US stocks,stocks and options,australian trading platform,online broker australia,stock trading apps,mobile trading app,desktop trading,chess sponsored brokers,share trading platform","social":{"ogDescription":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/DNL.AU"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"AUS","license":"TBAU","edition":"fundamental","symbol":"DNL.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"DNL.AU\",,,,,undefined,":{"symbol":"DNL.AU","market":"AU","secType":"STK","nameCN":"Dyno Nobel Ltd","latestPrice":3.33,"timestamp":1770600992472,"preClose":3.19,"halted":0,"volume":3550316,"delay":0,"changeRate":0.04388714733542324,"nameEN":"Dyno Nobel Ltd","floatShares":1650752404,"shares":1787087654,"eps":-0.027827,"marketStatus":"Trading","change":0.14,"latestTime":"02-09 12:36:40 AEDT","open":3.24,"high":3.34,"low":3.24,"amount":11641316,"amplitude":0.031348,"askPrice":3.34,"askSize":59098,"bidPrice":3.33,"bidSize":16094,"shortable":3,"etf":0,"ttmEps":-0.027827,"tradingStatus":2,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1770613200000},"marketStatusCode":2,"adr":0,"exchange":"ASX","adjPreClose":3.19,"dividendRate":0.035736,"openAndCloseTimeList":[[1770591600000,1770613200000]],"volumeRatio":1.332006,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"DNL.AU\",,,,,undefined,":{"symbol":"DNL.AU","floatShares":1650752404,"roa":"4.16%","roe":"3.20%","lyrEps":-0.027827,"volumeRatio":1.332006,"shares":1787087654,"dividePrice":0.119,"high":3.34,"amplitude":0.031348,"preClose":3.19,"low":3.24,"week52Low":2.062,"pbRate":"1.34","psRate":"1.58","week52High":3.6,"institutionHeld":0,"latestPrice":3.33,"committee":-0.571923,"eps":-0.027827,"divideRate":0.035736,"volume":3550316,"delay":0,"ttmEps":-0.027827,"open":3.24,"prevYearClose":3.21,"prevWeekClose":3.19,"prevMonthClose":3.51,"prevQuarterClose":3.21,"fiveDayClose":3.47,"twentyDayClose":3.39,"sixtyDayClose":3.334,"dividendPayoutRate":0.936430258489434,"dividendGrowthYears":0,"dividendGrowthRate":-0.7517385435898608,"fiveYearAvgDividendRate":0.06308596836097989},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/DNL.AU\",params:#limit:5,,,undefined,":[{"date":"2025-12-01","symbol":"DNL.AU","amount":0.095,"announcedDate":"2025-11-10","type":"dividend","lastAmount":null,"market":"AU","newRecordDate":"2025-12-02","name":"Dyno Nobel Ltd","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-16","payableDate":"2025-12-02","currency":"AUD","dateTimestamp":1764507600000,"payDate":"2025-12-16"},{"date":"2025-11-10","symbol":"DNL.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1762729200000,"name":null,"time":"","dateTimestamp":1762693200000,"actualEps":null},{"date":"2025-06-13","symbol":"DNL.AU","amount":0.024,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"AU","newRecordDate":"2025-06-16","defaultRemindTime":1749772800000,"name":"Dyno Nobel Ltd","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-07-03","payableDate":"2025-06-16","currency":"AUD","dateTimestamp":1749736800000,"payDate":"2025-07-03"},{"date":"2025-05-12","symbol":"DNL.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1747008000000,"name":null,"time":"","dateTimestamp":1746972000000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"DNL.AU\",market:\"AU\",,,undefined,":[{"executeDate":"2025-06-13","recordDate":"2025-06-16","paymentDate":"2025-07-03","value":0.024,"currency":"AUD"},{"executeDate":"2025-12-01","recordDate":"2025-12-02","paymentDate":"2025-12-16","value":0.095,"currency":"AUD"}],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"DNL.AU\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2608890407","title":"Dyno Nobel Ltd-Non-Executive Director Appointment","url":"https://stock-news.laohu8.com/highlight/detail?id=2608890407","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608890407?lang=en_us&edition=fundamental","pubTime":"2026-02-03 05:18","pubTimestamp":1770067112,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260202:nTUEQHZ0V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7025","DNL.AU"],"gpt_icon":0},{"id":"2607208545","title":"Ascletis Announces Positive Topline Results from Its Phase III Open-Label Study of Denifanstat (ASC40), a First-in-Class, Once-Daily Oral FASN Inhibitor for Acne","url":"https://stock-news.laohu8.com/highlight/detail?id=2607208545","media":"prnewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607208545?lang=en_us&edition=fundamental","pubTime":"2026-01-29 19:00","pubTimestamp":1769684400,"startTime":"0","endTime":"0","summary":"- Denifanstat , aonce-daily oral fatty acid synthase  inhibitor, demonstrated favorable safety and tolerability in a Phase III open-label study. - The exceptional efficacy of denifanstat  observed in the Company's previously reported placebo-controlled Phase III trial coupled with a favorable safety profile in two Phase III trials provide a potential major break-through for the treatment of acne. - New Drug Application for denifanstat  for acne was recently accepted by the China National Medical Products Administration. HONG KONG, Jan. 29, 2026 /PRNewswire/ -- Ascletis Pharma Inc.  today announced positive topline results from the Phase III open-label study  evaluating denifanstat , a first-in-class, once-daily oral small molecule fatty acid synthase  inhibitor, in patients with moderate-to-severe acne vulgaris.Ascletis Pharma Inc. is a fully integrated biotechnology company focused on the development and commercialization of potential best-in-class and first-in-class therapeutics to t","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/ascletis-announces-positive-topline-results-from-its-phase-iii-open-label-study-of-denifanstat-asc40-a-first-in-class-once-daily-oral-fasn-inhibitor-for-acne-302673870.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["III","BK7025","DNL","BK4134","DNL.AU"],"gpt_icon":0},{"id":"2606272751","title":"With 52% ownership in Dyno Nobel Limited (ASX:DNL), institutional investors have a lot riding on the business","url":"https://stock-news.laohu8.com/highlight/detail?id=2606272751","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606272751?lang=en_us&edition=fundamental","pubTime":"2026-01-28 04:54","pubTimestamp":1769547268,"startTime":"0","endTime":"0","summary":"Key Insights Institutions' substantial holdings in Dyno Nobel implies that they have significant influence over the...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/2022000-choice1-main-header/1585186586604","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/2022000-choice1-main-header/1585186586604"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/materials/asx-dnl/dyno-nobel-shares/news/with-52-ownership-in-dyno-nobel-limited-asxdnl-institutional","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/materials/asx-dnl/dyno-nobel-shares/news/with-52-ownership-in-dyno-nobel-limited-asxdnl-institutional","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["DNL.AU","DNL","BK7025"],"gpt_icon":0},{"id":"2602583980","title":"Insufficient Growth At Dyno Nobel Limited (ASX:DNL) Hampers Share Price","url":"https://stock-news.laohu8.com/highlight/detail?id=2602583980","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602583980?lang=en_us&edition=fundamental","pubTime":"2026-01-10 04:14","pubTimestamp":1767989653,"startTime":"0","endTime":"0","summary":"Dyno Nobel Limited's ( ASX:DNL ) price-to-sales (or \"P/S\") ratio of 1.6x might make it look like a strong buy right now...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/2022000-choice1-main-header/1585186586604","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/2022000-choice1-main-header/1585186586604"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/materials/asx-dnl/dyno-nobel-shares/news/insufficient-growth-at-dyno-nobel-limited-asxdnl-hampers-sha","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/materials/asx-dnl/dyno-nobel-shares/news/insufficient-growth-at-dyno-nobel-limited-asxdnl-hampers-sha","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["DNL.AU","BK7025","DNL"],"gpt_icon":0}],"pageSize":4,"totalPage":12,"pageCount":1,"totalSize":45,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/DNL.AU\",params:#limit:6,delay:true,,,undefined,":[]}}